RxDoctor Payments DataLook up a doctor →

Abdul Husein Bahrainwala, MD

Allergy & Immunology · Royal Oak, MINPI 1265465769

Payments from drug & device makers

$47,270in general payments, 2019–2025

Across 955 payments — averaging $49.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$27K
  • Genentech USA, Inc.$6K
  • GSK$3K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$931
  • plus $8K from 35 others

What the payments were for

  • Consulting fees$1,7254%
  • Speaking & faculty fees$27,95059%
  • Travel & lodging$3621%
  • Food & beverage$16,98436%
  • Education$2501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,270 in reported general payments places this provider in the 80th percentile of 119 allergy & immunology providers in Michigan.

See all allergy & immunology providers in Michigan

Medicare billing

Part B allowed, 2024
$814,845
Medicare patients
392
Services billed
27,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab69$245,167
NucalaMepolizumab20$170,424
TezspireTezepelumab-Ekko28$113,166
Dupixent PenDupilumab30$111,942
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$75,970
Spiriva RespimatTiotropium Bromide43$28,976
Breo ElliptaFluticasone/Vilanterol31$18,203
SymbicortBudesonide/Formoterol Fumarate46$12,487
Fluticasone-SalmeterolFluticasone Propion/Salmeterol70$11,777
Advair HfaFluticasone Propion/Salmeterol15$10,963
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$9,421
Epinephrine31$8,344
Tiotropium Bromide18$7,003
Azelastine Hcl206$6,548
Montelukast Sodium495$6,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$2,515$269,950171 claims
AstraZenecaTezspire, Symbicort, Breztri Aerosphere$27,246$135,07491 claims
Boehringer IngelheimSpiriva Respimat$334$28,97643 claims
Hikma Pharmaceuticals USAEpinephrine$49$8,34431 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$230$5,52815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 119 allergy & immunology providers in Michigan.

Other allergy & immunology in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →